Cencora (COR) said Monday it has entered into a definitive agreement to acquire a majority of OneOncology's outstanding equity interests it does not already own from TPG (TPG) and other shareholders.

The company said the transaction values OneOncology at about $7.4 billion, including an equity value of about $6 billion, and is expected to close by the end of its fiscal Q2 2026.

Cencora said it will pay about $3.6 billion for the outstanding equity interests and retire $1.3 billion of OneOncology's debt, for a total cash consideration of about $5 billion.

OneOncology's affiliated practices and management will retain a minority interest, the company said.

The company said it plans to fund the acquisition with new debt and prioritize deleveraging while maintaining investment-grade credit ratings.

Cencora said its full year adjusted diluted EPS will now likely be toward the lower half of its outlook range of $17.45 to $17.75.

The company raised its long-term guidance to reflect the expected contribution from OneOncology, increasing its adjusted diluted EPS growth outlook to 10% to 14%.